The earnings call highlighted significant achievements, such as the FDA approval of ZUSDURI and revenue growth for JELMYTO, alongside challenges including reimbursement issues and increased net loss. Despite some hurdles, the company's strong financial position and strategic initiatives for future growth contribute to a positive outlook.

Company Guidance -

Q3 2025

In the recent UroGen Pharma earnings call, the company provided detailed guidance regarding its commercial and clinical strategies. For the fiscal year 2025, UroGen aims to maintain net product revenues from JELMYTO between $94 million and $98 million, reflecting an 8% to 12% growth from the previous year, excluding $3 million from CREATES Act sales in 2024. Operating expenses for the year are projected to be between $215 million and $225 million, including $11 million to $14 million in noncash share-based compensation. The company has expanded its sales force to 82 territories and expects ZUSDURI, its newly FDA-approved treatment for recurrent low-grade intermediate risk non-muscle invasive bladder cancer, to drive growth with a total addressable market exceeding $5 billion annually. The ZUSDURI launch strategy is divided into two phases, with a broader adoption expected in 2026 following the anticipated assignment of a permanent J-code. UroGen also highlighted its strong balance sheet with $161.6 million in cash and marketable securities, positioning the company to support its strategic priorities.

FDA Approval of ZUSDURI

UroGen achieved a significant milestone with the FDA approval of ZUSDURI for adults with recurrent low-grade intermediate risk non-muscle invasive bladder cancer, marking a shift in treatment paradigms and transitioning UroGen into a multiproduct organization.

JELMYTO Revenue Growth

JELMYTO reported net product revenues of $24.2 million for Q2 2025, representing an 11% increase over the same period in 2024, driven by strong demand and acceptance among urologists.

Strong Financial Position

UroGen's balance sheet remains robust with $161.6 million in cash, cash equivalents, and marketable securities as of June 30, 2025, supporting the launch of ZUSDURI and advancement of the pipeline.

Successful Sales Team Expansion

The sales team was expanded from 50 to 82 territories to support the launch of ZUSDURI, positioning UroGen to effectively penetrate the $5 billion annual market.

Positive Clinical Data for ZUSDURI

In the Phase III ENVISION trial, 79% of patients achieved a complete response at 3 months, with a 24-month duration of response of 72.2% by Kaplan-Meier estimate, showcasing long-term disease control.

Urogen Pharma (URGN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

URGN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 17, 2025	2025 (Q3)	-0.64 / -	-0.55	―	―	―
Aug 07, 2025	2025 (Q2)	-0.86 / -1.05	-0.91	-15.38% (-0.14)	―
May 12, 2025	2025 (Q1)	-0.80 / -0.92	-0.97	5.15% (+0.05)	―
Mar 10, 2025	2024 (Q4)	-0.72 / -0.80	-0.72	-11.11% (-0.08)	―
Nov 06, 2024	2024 (Q3)	-0.82 / -0.55	-0.68	19.12% (+0.13)	―
Aug 13, 2024	2024 (Q2)	-0.83 / -0.91	-1.03	11.65% (+0.12)	―
May 13, 2024	2024 (Q1)	-0.87 / -0.97	-1.3	25.38% (+0.33)	―
Mar 14, 2024	2023 (Q4)	-0.68 / -0.72	-1.22	40.98% (+0.50)	―
Nov 14, 2023	2023 (Q3)	-0.85 / -0.68	-1.13	39.82% (+0.45)	―
Aug 10, 2023	2023 (Q2)	-1.14 / -1.03	-1.18	12.71% (+0.15)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

URGN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$20.01	$18.59	-7.10%
May 12, 2025	$10.38	$11.14	+7.32%
Mar 10, 2025	$9.82	$9.92	+1.02%
Nov 06, 2024	$12.21	$12.24	+0.25%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Urogen Pharma (URGN) report earnings?

Urogen Pharma (URGN) is schdueled to report earning on Nov 17, 2025, Before Open (Confirmed).

What is Urogen Pharma (URGN) earnings time?

Urogen Pharma (URGN) earnings time is at Nov 17, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is URGN EPS forecast?

URGN EPS forecast for the fiscal quarter 2025 (Q3) is -0.64.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing